1. Startpage
  2. Johannes Gutenberg-Universität Mainz
  3. DFG-OA-Publizieren (2012 - 2017)
Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-7863
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKlöckner, Roman-
dc.contributor.authorRuckes, Christian-
dc.contributor.authorKronfeld, Kai-
dc.contributor.authorWörns, Marcus-Alexander-
dc.contributor.authorWeinmann, Arndt-
dc.contributor.authorGalle, Peter R.-
dc.contributor.authorLang, Hauke-
dc.contributor.authorOtto, Gerd-
dc.contributor.authorEichhorn, Waltraud-
dc.contributor.authorSchreckenberger, Mathias-
dc.contributor.authorDüber, Christoph-
dc.contributor.authorPitton, Michael B.-
dc.date.accessioned2022-10-06T07:05:31Z-
dc.date.available2022-10-06T07:05:31Z-
dc.date.issued2014-
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/7878-
dc.description.abstractBACKGROUND: Cholangiocellular carcinoma is the second most common primary liver cancer after hepatocellular carcinoma. Over the last 30 years, the incidence of intrahepatic cholangiocellular carcinoma has risen continuously worldwide. Meanwhile, the intrahepatic cholangiocellular carcinoma has become more common than the extrahepatic growth type and currently accounts for 10-15% of all primary hepatic malignancies. Intrahepatic cholangiocellular carcinoma is typically diagnosed in advanced stages due to late clinical symptoms and an absence of classic risk factors. A late diagnosis precludes curative surgical resection. There is evidence that transarterial chemoembolization leads to better local tumor control and prolongs survival compared to systemic chemotherapy. New data indicates that selective internal radiotherapy, also referred to as radioembolization, provides promising results for treating intrahepatic cholangiocellular carcinoma. METHODS/DESIGN: This pilot study is a randomized, controlled, single center, phase II trial. Twenty-four patients with intrahepatic cholangiocellular carcinoma will be randomized in a 1:1 ratio to receive either chemoembolization or radioembolization. Randomization will be stratified according to tumor load. Progression-free survival is the primary endpoint; overall survival and time to progression are secondary endpoints. To evaluate treatment success, patients will receive contrast enhanced magnetic resonance imaging every 3 months. DISCUSSION: Currently, chemoembolization is routinely performed in many centers instead of systemic chemotherapy for treating intrahepatic cholangiocellular carcinoma confined to the liver. Recently, radioembolization has been increasingly applied to cholangiocellular carcinoma as second line therapy after TACE failure or even as an alternative first line therapy. Nonetheless, no randomized studies have compared radioembolization and chemoembolization. Considering all this background information, we recognized a strong need for a randomized controlled trial (RCT) to compare the two treatments. Therefore, the present protocol describes the design of a RCT that compares SIRT and TACE as the first line therapy for inoperable CCC confined to the liver.en_GB
dc.description.sponsorshipDFG, Open Access-Publizieren Universität Mainz / Universitätsmedizinde
dc.language.isoengde
dc.rightsCC BY*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleSelective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC) : study protocol for a randomized controlled trialen_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-7863-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.number2700-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleTrialsde
jgu.journal.volume15de
jgu.pages.alternativeArt. 311de
jgu.publisher.year2014-
jgu.publisher.nameBioMed centralde
jgu.publisher.placeLondonde
jgu.publisher.urihttp://dx.doi.org/10.1186/1745-6215-15-311de
jgu.publisher.issn1468-6694de
jgu.publisher.issn1745-6215de
jgu.publisher.issn1468-6708de
jgu.organisation.placeMainz-
jgu.identifier.pmid25095718-
jgu.subject.ddccode610de
opus.date.modified2018-08-08T09:12:34Z-
opus.subject.dfgcode00-000-
opus.organisation.stringFB 04: Medizin: Klinik und Poliklinik für Diagnostische und Interventionelle Radiologiede_DE
opus.organisation.stringFB 04: Medizin: Klinik und Poliklinik für Nuklearmedizinde_DE
opus.organisation.stringFB 04: Medizin: I. Medizinische Klinik und Poliklinikde_DE
opus.organisation.stringFB 04: Medizin: Klinik und Poliklinik für Allgemein- und Abdominal-Chirurgiede_DE
opus.organisation.stringFB 04: Medizin: Abteilung für Transplantationschirugiede_DE
opus.organisation.stringFB 04: Medizin: Interdisziplinäres Zentrum Klinische Studien Mainz (IZKS)de_DE
opus.identifier.opusid27387-
opus.importsourcepubmed-
opus.institute.number0419-
opus.institute.number0422-
opus.institute.number0425-
opus.institute.number0436-
opus.institute.number0440-
opus.institute.number0460-
opus.metadataonlyfalse-
opus.type.contenttypeKeinede_DE
opus.type.contenttypeNoneen_EN
opus.affiliatedKlöckner, Roman-
opus.affiliatedRuckes, Christian-
opus.affiliatedWeinmann, Arndt-
opus.affiliatedLang, Hauke-
opus.affiliatedEichhorn, Waltraud-
opus.affiliatedSchreckenberger, Mathias-
opus.affiliatedDüber, Christoph-
opus.affiliatedPitton, Michael B.-
jgu.publisher.doi10.1186/1745-6215-15-311de
jgu.organisation.rorhttps://ror.org/023b0x485-
Appears in collections:DFG-OA-Publizieren (2012 - 2017)

Files in This Item:
  File Description SizeFormat
Thumbnail
selective_internal_radiothera-20220914234950293.pdf454.71 kBAdobe PDFView/Open
Show simple item record